



# STRong Heart

Strengthening Trials and Research  
for Rheumatic Heart Disease



## Prof Ganesan Karthikeyan

Transitional Health, Science and Technology  
India Co-I

Adult Cardiologist and Specialist Scientist

**Qualifications:** MBBS, MD, DM (Cardiology), MSc (Health Research Methodology)

---

### About

Professor Karthikeyan is a clinical cardiologist and a Professor of Cardiology at the All India Institute of Medical Sciences, New Delhi, India. He is currently serving as the Executive-Director of Transitional Health, Science and Technology (THSTI), an institute of BRIC, Department of Biotechnology, Ministry of Science and Technology. He completed his training at the All India Institute of Medical Sciences, New Delhi, and at McMaster University, Canada. He is a Senior International Fellow of the Population Health Research Institute at McMaster University, Fellow of the Academy of Medical Sciences, National Academy of Sciences India (NASI), the Indian National Science Academy (INSA), and a Fellow of the Royal College of Physicians, London. He is the Editor-in-Chief of the BMJ journal Open Heart and an Associate Editor of several other international cardiology journals. His research is mainly focused on cardiovascular diseases affecting low- and middle-income countries, including valvular heart disease, particularly rheumatic heart disease (RHD), mechanical valve thrombosis, anticoagulation, and imaging in coronary artery disease. He has over 200 peer-reviewed publications in international journals including the New England Journal of Medicine, Lancet, and JAMA, is among the top 2% of the most cited scientists in the world. He is a member of the Medical Technology Assessment Board (MTAB) of the Government of India, the Chair of the Technical Advisory Group reviewing cost-effectiveness of drugs and technologies for deployment, and a member of the expert panel devising cardiology reimbursement packages for the Indian government's flagship insurance scheme, PMJAY. He is a member of the Governing Board of Rheumatic Heart Disease, Evidence, Advocacy, Communication, Hope (Reach), and also serves as an honorary consultant to the Human Health Division of the International Atomic Energy Agency (IAEA), providing advice in identifying, designing and implementing research protocols in resource-poor settings.

---